PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population

Area of Science:

• Immunology
• Oncology
• Flow Cytometry

Background:

• Immune checkpoint expression on mantle cell lymphoma (MCL) cells is poorly understood.
• Ambiguous findings hinder the use of immune checkpoint inhibitors (ICIs) in MCL therapy.

Purpose of the Study:

• To investigate the surface expression of PD-1, PD-L1, and PD-L2 on B and T cells in MCL patients.
• To compare expression levels with chronic lymphocytic leukemia (CLL) and healthy controls.
• To explore age-dependent changes in immune checkpoint expression in healthy individuals.

Main Methods:

• Multiparameter flow cytometry was used to analyze PD-1, PD-L1, and PD-L2 expression.
• Samples were obtained from 31 newly diagnosed MCL patients, 26 newly diagnosed CLL patients, and 20 healthy volunteers.
• A subanalysis of 30 healthy volunteers (ages 25-93) examined age-related expression changes.

Main Results:

• Mantle cell lymphoma patients exhibited weak (<10%) surface expression of PD-1, PD-L1, and PD-L2 on B and T cells compared to healthy individuals.
• Healthy volunteers showed a significant age-dependent increase in PD-1 and PD-L2 expression.
• Chronic lymphocytic leukemia data was also collected for comparison.

Conclusions:

• PD-1 and its ligands (PD-L1, PD-L2) are unlikely to be effective therapeutic targets in mantle cell lymphoma.
• Age-related changes in immune checkpoint expression in the healthy population may influence ICI efficacy and cancer incidence.
• Further research is needed to understand the clinical implications of these age-dependent changes.